Program
EZH1/2 Inhibitor HH2853
Its studies are mostly in Lymphoma, T-Cell, Peripheral · Lymphoma, Follicular, led by Haihe Biopharma.
Furthest: phase 2, since May 6, 20202 company-led studies, 2 open or runningNext primary completion: Dec 31, 2027 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Haihe Biopharma | 22 open or running | phase 2since May 6, 2020 | May 6, 2020 | Dec 31, 2027phase 2 · NCT04390737 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- May 6, 2020First study: phase 2 study in Lymphoma, FollicularFirst studyNCT04390737 · 254 planned · United States, China
- Mar 20, 2025Phase 2 study in RecurrenceNCT06909877 · 100 planned · China
Ahead
- Dec 31, 2027Primary completion: phase 2 study in Lymphoma, FollicularNCT04390737
TargetBeta
“An orally bioavailable inhibitor of the histone lysine methyltransferases enhancer of zeste homolog 1 (EZH1) and 2 (EZH2), ”NCIt, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| tulmimetostat | Novartis | phase 2 | 3 |
| valemetostatrule | Daiichi Sankyo | phase 1 | 1 |
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06909877Recurrence · China | 2 | Recruiting | Oct 31, 2025 | 100 |
| NCT04390737Lymphoma, Follicular · United States, China | 2 | Recruiting | Dec 31, 2027 | 254 |
How it is read
Names in the registry
- “HH2853 Tablets”, 2 entries
Conditions, from the studies’ own filings
- Lymphoma, T-Cell, Peripheral, 1 study
- Lymphoma, Follicular, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.